Dr Reddy's in pink of health after Haleon's NRT biz acquisition
Business Standard|June 28, 2024
Dr Reddy's Laboratories (DRL) is set to acquire Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside of the US.
DEVANGSHU DATTA
Dr Reddy's in pink of health after Haleon's NRT biz acquisition

DRL will pay a total consideration of £500 million, including an upfront cash consideration of £458 million and contingent cash payments up to £42 million based on performances in CY25 and CY26.

DRL will acquire the portfolio through the purchase of shares of Northstar Switzerland SARL, a Haleon group firm.

The purchase will be funded through internal accruals. The portfolio had net revenue of £217 million in CY23, the operating profit margin was 25 per cent, and the deal valuation was 2.3 times of sales. The transaction is expected to close in Q4CY24.

In the recent years, DRL has increased its global presence in consumer healthcare including a recent JV with Nestlé India.

This story is from the June 28, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the June 28, 2024 edition of Business Standard.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BUSINESS STANDARDView All
Business Standard

India, US extend 2% digital tax pact on e-commerce

India and the United States have decided to extend the agreement relating to 2 per cent equalisation levy, or digital tax, imposed by New Delhi on e-commerce platforms till June 30, the finance ministry said on Friday.

time-read
1 min  |
June 29, 2024
Brokerages turn bullish on telcos after tariff hike
Business Standard

Brokerages turn bullish on telcos after tariff hike

Bharti Artel and Reliance Jio (RJio) announced a hike in tariffs across telecom plans with effect from July 3.

time-read
2 mins  |
June 29, 2024
Business Standard

Emcure Pharma looks to raise ₹1,952 cr via IPO

Emcure Pharmaceuticals has set a price band of ₹960-1,008 per share for its initial public offering (IPO) that opens for subscription on July 3.

time-read
1 min  |
June 29, 2024
Business Standard

ICICI Prudential MF launches energy fund with eye on demand growth

ICICI Prudential Mutual Fund (MF) has announced the launch of Energy Opportunities Fund, a thematic scheme which will look to ride the energy growth demand wave and capture the emerging opportunities in the renewables space.

time-read
1 min  |
June 29, 2024
Geopolitics biggest risk to markets: Chris Wood
Business Standard

Geopolitics biggest risk to markets: Chris Wood

Geopolitics, particularly, the growing risk of escalation in the Russia-Ukraine conflict, remains by far the biggest risk the markets, wrote Christopher Wood (pictured), global head of equity strategy at Jefferies in his weekly note to investors, GREED & fear.

time-read
1 min  |
June 29, 2024
Business Standard

Indices snap winning streak

Equity benchmark Sensex on Friday fell for the first time in seven days, while the Nifty 50 index notched up its first loss in five days.

time-read
1 min  |
June 29, 2024
Business Standard

Navigating the hype-reality divide

It has been an education watching the T20 World Cup and the Euro on my mobile.

time-read
3 mins  |
June 29, 2024
Business Standard

Attracting Netravalkars

EYE CULTURE VISHAL MENON The average Indian male loathes Saurabh Netravalkar.

time-read
3 mins  |
June 29, 2024
Business Standard

A new paradigm for creating jobs

It would be prudent to take up a few sectors initially, get the policy instruments right, and put in the critical mass of resources to achieve a self-sustaining inflection point

time-read
4 mins  |
June 29, 2024
Business Standard

Three elections, three mistakes

Joe Biden had a disastrous evening on the debate stage on Thursday.

time-read
3 mins  |
June 29, 2024